Login / Signup

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

Joop M A Van GervenMilton Bonelli
Published in: British journal of clinical pharmacology (2018)
Keyphrases
  • clinical trial
  • endothelial cells
  • phase ii
  • induced pluripotent stem cells
  • open label
  • climate change